Voyager Therapeutics (NASDAQ:VYGR) Upgraded by StockNews.com to “Buy” Rating

StockNews.com upgraded shares of Voyager Therapeutics (NASDAQ:VYGR) from a hold rating to a buy rating in a research note published on Monday.

VYGR has been the subject of a number of other reports. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners initiated coverage on Voyager Therapeutics in a report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective on the stock. Leerink Partnrs raised Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Wedbush lowered their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $14.00 price objective on shares of Voyager Therapeutics in a research note on Thursday, November 14th. One analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $17.00.

Voyager Therapeutics Stock Down 4.5 %

NASDAQ:VYGR opened at $5.39 on Monday. The stock has a market capitalization of $294.18 million, a PE ratio of 7.58 and a beta of 0.89. Voyager Therapeutics has a 52 week low of $5.38 and a 52 week high of $11.72. The stock’s 50-day moving average price is $6.62 and its 200-day moving average price is $7.49.

Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.29. The company had revenue of $24.63 million for the quarter, compared to analyst estimates of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period last year, the company earned ($0.59) earnings per share. Sell-side analysts expect that Voyager Therapeutics will post -1.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Voyager Therapeutics news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The shares were sold at an average price of $5.82, for a total transaction of $34,914.18. Following the transaction, the insider now directly owns 86,001 shares of the company’s stock, valued at $500,525.82. The trade was a 6.52 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Institutional Trading of Voyager Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in VYGR. Vanguard Group Inc. lifted its holdings in Voyager Therapeutics by 27.8% in the first quarter. Vanguard Group Inc. now owns 3,231,698 shares of the company’s stock valued at $30,087,000 after acquiring an additional 702,030 shares during the last quarter. Great Point Partners LLC purchased a new stake in Voyager Therapeutics in the second quarter valued at $12,668,000. Armistice Capital LLC lifted its stake in shares of Voyager Therapeutics by 11.3% in the 2nd quarter. Armistice Capital LLC now owns 5,200,000 shares of the company’s stock valued at $41,132,000 after purchasing an additional 528,000 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Voyager Therapeutics by 3.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,041,930 shares of the company’s stock valued at $9,702,000 after purchasing an additional 37,144 shares during the last quarter. Finally, Patriot Financial Group Insurance Agency LLC purchased a new position in shares of Voyager Therapeutics during the 2nd quarter worth $1,012,000. Institutional investors and hedge funds own 48.03% of the company’s stock.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.